Daunorubicin Plus Cytarabine 3+5 Regimen Combined with Venetoclax in De Novo Patients with Acute Myeloid Leukemia: a Single Center, Open-label, Controlled Study

This study is a non-profit, prospective, single-center, open-label, controlled clinical trial aimed at evaluating the efficacy of the daunorubicin, cytarabine, and venetoclax (DAV) regimen in previously untreated adult AML patients eligible for intensive chemotherapy.The combination of daunorubicin administered for 3 consecutive days and cytarabine for 7 consecutive days constitutes the classic "3+7" induction chemotherapy regimen for AML patients eligible for chemotherapy. The addition of venetoclax to the "3+7" regimen has shown promising efficacy in newly diagnosed AML patients suitable for intensive therapy. However, this approach is associated with increased adverse reactions. Based on current clinical studies, we propose a modified approach involving reduced-dose chemotherapy combined with venetoclax for AML treatment, aiming to achieve optimal efficacy while effectively reducing adverse reactions.

Start Date01 Feb 2025

Sponsor / Collaborator

Anhui Medical University

[+1]

NCT06210750

/ WithdrawnPhase 2IIT

A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma

This phase II trial tests the safety and effectiveness of giving chemotherapy with or without venetoclax and/or navitoclax for the treatment of patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and navitoclax are in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. They may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving chemotherapy with or without venetoclax and/or navitoclax may be effective treatments for patients with newly diagnosed T-ALL or T-LBL.

Start Date09 Aug 2024

Sponsor / Collaborator

National Cancer Institute

NCT06516679

/ Not yet recruitingPhase 2IIT

Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia: A Multicenter, Prospective Study

This clinical trial is an open-label, multicenter, prospective phase 2 clinical trial targeting pediatric leukemia patients of infant age. The goal is to improve survival rates by varying the presence or absence of chemotherapy and hematopoietic stem cell transplantation based on genetic characteristics at the time of diagnosis and minimal residual disease (MRD) values measured by various methods after treatment.
In addition, by clearly defining the patient group that requires hematopoietic stem cell transplantation, it is expected that the role of hematopoietic stem cell transplantation in infantile leukemia, for which there have been various guidelines for hematopoietic stem cell transplantation, can be confirmed. Additionally, due to the characteristics of infants, this study aim to identify long-term sequelae or prognosis related to treatment by prospectively collecting side effect data related to treatment during and after treatment.

Start Date01 Aug 2024

Sponsor / Collaborator

Yonsei University

100 Clinical Results associated with Acetyladriamycin

100 Translational Medicine associated with Acetyladriamycin

100 Patents (Medical) associated with Acetyladriamycin

10,070

Literatures (Medical) associated with Acetyladriamycin

01 May 2025·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

Beyond DNA interactions: Insights into idarubicin's binding dynamics with tRNA using spectroscopic and computational approaches

Article

Author: Srivastava, Chandra Mohan ; Asthana, Shailendra ; Shandilya, Manish ; Kumar, Dhruv ; Mittal, Lovika ; Charak, Sonika ; Mehrotra, Ranjana

Idarubicin (4-demethoxydaunomycin), a structural analogue of daunomycin derived from Streptomyces peucetius, exhibits enhanced anticancer efficacy due to the substitution of a methoxy group with a hydrogen atom. This study investigates the binding interactions of idarubicin with RNA using a multifaceted approach, including infrared (IR) spectroscopy, absorption spectroscopy, circular dichroism (CD), molecular docking, and molecular dynamics (MD) simulations. The IR results demonstrate significant binding to guanine and uracil, indicated by spectral shifts, while MD simulations reveal additional interactions with adenine, highlighting a flexible binding mechanism. The binding constant of the idarubicin-RNA complex was calculated to be K = 2.1 × 10³ M^-1, reflecting a strong affinity and stable interaction. Thermodynamic analysis shows that the negative Gibbs free energy (ΔG ∼ -4.57 kcal/mol) signifies spontaneous binding under physiological conditions. The binding free energy estimation was carried out to check the binding affinity, stability and interactions of the complex which was assessed through molecular dynamics simulations. The stability of the idarubicin-RNA complex is further supported by a hyperchromic effect observed in absorption spectroscopy, suggesting effective intercalation that enhances base exposure. The binding is driven by hydrogen bonding, π-π stacking interactions, and electrostatic forces, which collectively stabilize the complex. Notably, the conformational integrity of RNA is largely preserved, with key structural features remaining unchanged in both IR and CD analyses. Comparatively, idarubicin's interactions with RNA differ from those with DNA, where the latter shows more substantial conformational perturbations. These findings enhance our understanding of anthracycline functionality and provide valuable insights for developing novel analogues with improved efficacy and reduced side effects, informing future therapeutic strategies targeting RNA in cancer treatment.

01 Apr 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Functional and structural polypharmacology of indazole-based privileged ligands to tackle the undruggability of membrane transporters

Article

Author: Bakos, Éva ; Zhang, Bohan ; Rafehi, Muhammad ; Stefan, Katja ; Chen, Xiang ; Busch, Hauke ; Neif, Maria ; Ismail Al-Khalil, Wouroud ; Stefan, Sven Marcel ; Juvale, Kapil ; Namasivayam, Vigneshwaran ; Chen, Zhe-Sheng ; Yazdi, Zeinab Nezafat ; Özvegy-Laczka, Csilla ; Arlt, Nike Sophia ; Puri, Sachin ; Latambale, Ganesh ; Tägl, Franziska

Despite the significant roles of solute carrier (SLC) and ATP-binding cassette (ABC) transporters in human health and disease, most remain poorly characterized as intrinsic and/or xenobiotic ligands are unknown, rendering them as 'undruggable'. Polypharmacology, defined as the simultaneous engagement of multiple targets by a single ligand, offers a promising avenue for discovering novel lead compounds addressing these emerging pharmacological challenges - a major focus in contemporary medicinal chemistry. While common structural motifs among phylogenetically diverse proteins have been proposed to underlie polypharmacology through the concept of 'multitarget binding sites', a comprehensive analysis of these functional and structural aspects from a medicinal chemistry perspective has yet to be undertaken. In our study, we synthesized 65 distinct indazole derivatives and evaluated their activity across a broad biological assessment platform encompassing 17 specific and polyspecific SLC and ABC transporters. Notably, ten indazoles exhibited cross-target activity against challenging transporter targets associated with neurodegeneration (ABCA1), metabolic reprogramming (MCT4), and cancer multidrug resistance (ABCC10). Furthermore, molecular blind docking experiments and advanced binding site analyses revealed, for the first time, conserved binding motifs across monocarboxylate transporters (MCTs), organic anion transporting polypeptides (OATPs), organic cation transporters (OCTs), and ABC transporters, characterized by specific and recurring residues of tyrosine, phenylalanine, serine, and threonine. These findings highlight not only the potential of polypharmacology in drug discovery but also provide insights into the structural underpinnings of ligand binding across membrane transporters.

01 Mar 2025·BIOMEDICAL MICRODEVICES

Retraction Note: Label-free microfluidic chip for segregation and recovery of circulating leukemia cells: clinical applications in acute myeloid leukemia

Author: Li, Yonghua ; Chao, Shuen ; Hu, Lina ; Wang, Yiyang ; Tang, Bin ; Yarmush, Martin ; Ye, Ningxin ; Jiang, Yue ; Tuner, Memet ; Ouyang, Dongfang

We present a label-free microfluidic chip for the segregation of circulating leukemia cells (CLCs) from blood samples, with a focus on its clin. applications in Acute Myeloid Leukemia (AML).The microfluidic chip achieved an approx. capture efficiency of 92%.The study analyzed a comprehensive set of 66 blood specimens from AML patients in different disease stages, including newly diagnosed and relapsing cases, patients in complete remission, and those in partial remission.The results showed a significant difference in CLC counts between active disease stages and remission stages (p < 0.0001), with a proposed threshold of 5 CLCs to differentiate between the two.The microfluidic chip exhibited a sensitivity of 95.4% and specificity of 100% in predicting disease recurrence.Addnl., the captured CLCs were subjected to downstream mol. anal. using droplet digital PCR, allowing for the identification of genetic mutations associated with AML.Comparative anal. with bone marrow aspirate processing by FACS demonstrated the reliability and accuracy of the microfluidic chip in tracking disease burden, with highly agreement results obtained between the two methods.The non-invasive nature of the microfluidic chip and its ability to provide real-time insights into disease progression make it a promising tool for the proactive monitoring and personalized patient care of AML.

News (Medical) associated with Acetyladriamycin

02 Nov 2022

·www.biospace.com

CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Enrollment progressing toward interim analysis, planned when 30-50% of subjects reach 6 months in study HOUSTON, Nov. 2, 2022 /PRNewswire/ -- CNS PHARMACEUTICALS AG (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the first patient in Europe has been enrolled and dosed in France in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company has opened 29 clinical trial sites of the 68 sites selected across the U.S., Italy, France, Spain, and Switzerland. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis. "Our team has worked tirelessly to expand the presence of our clinical trial for Berubicin on a global scale. To have enrolled and dosed our first patient in France shortly after the opening the site is a noteworthy accomplishment and a testament to our team's dedication to drive the program forward. I am pleased with the progress made and remain committed to building on this momentum. We expect to enroll and dose additional patients across our clinical trial sites in Europe and advance toward the much-anticipated inflection point which is the interim analysis," commented John Climaco, CEO of CNS Pharmaceuticals. Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. The potentially pivotal trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV1) after failure of standard first-line therapy. The primary endpoint of the study is Overall Survival (OS), which is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Results from the trial will compare Berubicin to a current standard of care (Lomustine), with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine. The recently amended protocol expands eligibility for the study to patients who have received additional treatments as part of the first line therapy for their disease considering advancements in this area. This change was made due to the complexity of new agents introduced as a component of first line therapy, which allows an additional group of patients that can enroll on the study after what may constitute multiple procedures as their initial treatment. For more information about the potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069. The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with them to provide guidance on expediting the development and review process. Additionally, the Company has also received Orphan Drug Designation from the FDA which may provide seven years of marketing exclusivity upon approval of an NDA. About Berubicin Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, please visit , and connect with the Company on Twitter, Facebook, and LinkedIn. Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company's ability to enroll and dose additional patients across clinical trial sites in Europe on a timely basis. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Codes: NASDAQ-NMS:CNSP

Orphan DrugSmall molecular drugFast Track

10 Oct 2022

·www.prnewswire.com

CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run

HOUSTON, Oct. 10, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in The American Brain Tumor Association's Breakthrough for Brain Tumors® 5K Run taking place Saturday, November 5, 2022 in Los Angeles, CA. "The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS I have come to know many brain tumor patients personally and the optimism and strength with which they have all faced this terrible diagnosis is a continuing source of inspiration to me. Supporting these patients, their journey and the challenges they currently endure is not just a priority for us, it is why we do what we do," commented John Climaco, CEO of CNS Pharmaceuticals. "Across the globe there is an urgent need for safe and effective GBM treatment options, and I am proud to participate in the BT5K to support the mission of the ABTA, to help bring hope to patients and families and to raise much needed funds for research." The American Brain Tumor Association's BT5K offers the opportunity to support the ABTA mission to advance the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis. As part of participating in the event, donations are being accepted to further research which can benefit all patients and provide critical funding for brain tumor research and for supporting patient care. If you would like to make a donation, please visit here. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, please visit , and connect with the Company on Twitter, Facebook, and LinkedIn. SOURCE CNS Pharmaceuticals, Inc.

Small molecular drug

07 Oct 2022

·www.biospace.com

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM

LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire --CNS PHARMACEUTICALS AG (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers CNS Pharmaceuticals’ recent announcement highlighting the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. To hear the audio production, visit: To read the original press release, visit: “Our primary focus continues to be on advancing the clinical development of Berubicin as a potential treatment option for this devastating disease. Over the course of this year, we have worked diligently to expand patient eligibility for our potentially pivotal trial and bolster our international presence now realized with the activation of the first two European clinical trial sites,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “This is a true testament to our team's commitment to and the execution of this important clinical program.” Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. The potentially pivotal trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV1) after failure of standard first-line therapy. The primary endpoint of the study is Overall Survival (OS), which is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Results from the trial will compare Berubicin to a current standard of care (Lomustine), with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine. “We are grateful for the tremendous support from the clinical staff and remain dedicated to driving patient enrollment as quickly and efficiently as possible. We look forward to continuing to build momentum and bringing Berubicin across the finish line to unlock its greatest potential. As long as the unmet medical need in GBM remains, we will continue our fight in earnest to bring hope to patients and families globally,” Climaco added. As detailed in the news release, the FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin, which enables more frequent interactions with them to provide guidance on expediting the development and review process. Additionally, the company has also received Orphan Drug Designation from the FDA, which may provide seven years of marketing exclusivity upon approval of an NDA. About CNS Pharmaceuticals Inc. CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, please visit , and connect with the company on Twitter, Facebook, and LinkedIn. About NetworkNewsAudio NetworkNewsAudio (“NNA”), one of 50+ brands within IBN (InvestorBrandNetwork), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation. For more information, visit: Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of enrollment of new patients and the ability of the Company to complete the trial on a timely basis, if at all. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California 310.299.1717 Office Editor@InvestorBrandNetwork.com

Orphan DrugSmall molecular drugFast Track

100 Deals associated with Acetyladriamycin

External Link

KEGG	Wiki	ATC	Drug Bank
D10787	-	L01DB02	DB00694

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kaposi Sarcoma	France	Galen US, Inc.	19 Aug 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 2	United States	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Belgium	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Canada	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Denmark	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	France	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Israel	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Italy	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Netherlands	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Spain	Daiichi Sankyo Co., Ltd.	15 Aug 2018
Acute Myeloid Leukemia	Phase 2	Sweden	Daiichi Sankyo Co., Ltd.	15 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCRI AML18 (ASH2024)	Phase 2	Acute Myeloid Leukemia MDS-related gene mutations	506	CPX-351	fzipdxmhvc(nsxtvqzhyb) = ssmrrgattx lypnidmohx (dsfotdcjdr, 0.57 - 0.93) View more	Negative	07 Dec 2024
				DAGO2	fzipdxmhvc(nsxtvqzhyb) = htdhravgld lypnidmohx (dsfotdcjdr, 0.73) View more
NCT03724084 (CTgov)	Phase 1/2	Acute Myeloid Leukemia	6	Daunorubicin+Pinometostat+Cytarabine+Daunorubicin Hydrochloride (Cohort II (Higher Dose Pinometostat))	igdbeqpotd = hngmwfxogj zpfayubzuu (eiidorpygj, bltqajuyfy - xxiffsqgrf) View more	-	11 Jun 2024
				Daunorubicin+Pinometostat+Cytarabine+Daunorubicin Hydrochloride (Cohort I (Higher and Lowers Dose Pinometostat))	hmakanvvbf(kiavzlfzgz) = wjexfttypp bwgibaahus (tmgpumrfpj, ssqpvogyyl - wkerjsgtqu) View more
NCT00866749 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia \| Adult Lymphoblastic Lymphoma	120	Daunorubicin+cyclophosphamide+doxorubicin+PEG-asparaginase+Thioguanine+Mercaptopurine+Methotrexate+Vincristine+Cytarabine	llzhplnhay = ynmtikzmba mnyofmbcmu (uonqdihxwh, mzowmsdedm - gsxcpraxap) View more	-	10 Sep 2019
NCT00610883 (CTgov)	Phase 2	Non-Hodgkin Lymphoma	17	LSA4+Cyclophosphamide+Daunomycin+BCNU+Methotrexate	glbpkajjsa = gogttkttse tottfmtpcg (mkaivnntuq, verudfcfvd - xzvktvuhft) View more	-	25 Jan 2016
NCT00176462 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia	60	L-asparaginase+Daunomycin+cyclophosphamide+Hydrocortisone+6-thioguanine+aminopterin+6-mercaptopurine+Leucovorin+dexamethasone+Vincristine+Methotrexate+Cytarabine (Arm 2 High Risk)	xwlywddkgt = mwwxnqkjdj msgsymwtnv (rnkavhucig, mijzdbnnmt - spgwcodvbi) View more	-	09 Jun 2014
				L-asparaginase+Daunomycin+Hydrocortisone+6-mercaptopurine+Leucovorin+dexamethasone+Methotrexate+Vincristine+Cytarabine (Arm 1 Standard Risk)	fjcpbggmox(igmfxgdsln) = rtpigkgzzg hnnihqjzyk (zwmxzlphyl, xoylrkxckr - kmgnmmqmnr) View more
ASCO2005	Not Applicable	Colonic Cancer \| Prostatic Cancer \| Non-Small Cell Lung Cancer	21	Targeted liposomal daunorubicin (LDauno)	swepayavck(xdllhyenuh) = mmpjvdhxnf qvuzcnvnvk (uhzcjhdzem )	-	01 Jun 2005
				Filgrastim (F)	swepayavck(xdllhyenuh) = duaogpahrv qvuzcnvnvk (uhzcjhdzem )
IAS2004	Not Applicable	Kaposi Sarcoma	76	Liposomal Daunorrubicin (Daunoxome)	toztbbwblh(hainpukokx) = pancytopenia being the most frequent reported effects obcyvmfpbn (htsfdrkqoo ) View more	-	01 Jan 2004
				Liposomal Daunorrubicin (daunoxome) (Other treatment options)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis